JNJ vs KO: How Johnson & Johnson and Coca-Cola Compare (2026)

Same yardstick, side by side (as of July 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: JNJ is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. JNJ and KO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined JNJ and KO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Johnson & Johnson is one of the world's largest healthcare companies, now focused on two core areas after spinning off its consumer-health business (Kenvue). Its Innovative Medicine segment develops and sells branded prescription drugs across oncology, immunology, neuroscience, cardiovascular, and other areas, with major franchises that drive much of its profit. Its MedTech segment makes medical devices and surgical equipment for cardiovascular intervention, orthopedics, surgery, and vision care. J&J makes money by researching, manufacturing, and selling patented pharmaceuticals and devices to hospitals, physicians, pharmacies, and patients worldwide, supported by one of the largest research and development budgets in healthcare. The company is known for its diversification, financial strength, AAA-class balance sheet, and a multi-decade record of raising its dividend, making it a classic defensive blue chip. Founded in 1886 and headquartered in New Brunswick, New Jersey, J&J is a broadly held, large-cap healthcare company valued for stability, income, and a deep drug and device pipeline.

Full JNJ guide

The Coca-Cola Company is the world's largest non-alcoholic beverage company, built around a portfolio of more than 200 brands sold in over 200 countries. Its lineup spans sparkling soft drinks (Coca-Cola, Sprite, Fanta), water and sports drinks (Dasani, smartwater, Powerade, BODYARMOR), juices and dairy (Minute Maid, Simply, fairlife), coffee (Costa), and tea. Coca-Cola operates primarily as a brand owner and concentrate maker: it sells concentrates and syrups to a global network of independent and company-affiliated bottlers, who add water and packaging and handle local distribution. This asset-light model keeps Coca-Cola's margins high and capital needs low while the bottlers carry the heavier manufacturing and logistics costs. The company makes money through the spread on concentrate sales plus brand licensing and marketing scale. Founded in 1886 and headquartered in Atlanta, Georgia, Coca-Cola is a Dividend King with one of the longest continuous dividend-increase records of any public company, and a long-standing core holding of Berkshire Hathaway.

Full KO guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• JNJ drivers: Innovative Medicine pipeline; MedTech innovation and recovery.
• KO drivers: Unmatched global brand and distribution; Portfolio diversification beyond soda.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: J&J faces patent expirations on key drugs, including the eventual loss of exclusivity for major franchises, which requires the pipeline to continually replace lost revenue. For KO, coca-Cola faces secular pressure on sugary sodas from health trends, sugar taxes, and regulation in many markets.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick JNJ if you believe its drivers more; KO if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the JNJ and KO guides.

JNJ. J&J trades at a valuation typical of a large, defensive healthcare blue chip: a moderate multiple reflecting steady low-to-mid single-digit growth, high margins, and very strong cash generation, plus a discount for litigation and patent-cliff overhangs. The market values its diversification, balance-sheet strength, and long dividend record, pricing it as a stable income-and-quality holding rather than a growth stock.

KO. Coca-Cola trades at a premium to the typical staple, reflecting its globally dominant brand, high margins from the concentrate model, and a 60-plus-year dividend-increase record. The multiple embeds expectations of steady mid-single-digit organic growth and reliable cash returns. As a defensive, income-oriented name, its valuation is anchored by the dividend yield and tends to hold up in downturns and lag in strong risk-on markets.

Headline figures (approximate, early 2026): JNJ shows revenue (ttm) ~$90 billion, operating margin ~25%, net income (ttm) ~$15 billion, p/e (ttm) ~16x; KO shows revenue (ttm) ~$47 billion, operating margin ~30% (high, reflecting the asset-light concentrate model), net income (ttm) ~$11 billion, p/e (ttm) ~25x.

JNJ and KO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined JNJ and KO exposure against your real portfolio. It is not an investment adviser.